ZA202309330B - Method for analyzing a blood sample for a disease - Google Patents
Method for analyzing a blood sample for a diseaseInfo
- Publication number
- ZA202309330B ZA202309330B ZA2023/09330A ZA202309330A ZA202309330B ZA 202309330 B ZA202309330 B ZA 202309330B ZA 2023/09330 A ZA2023/09330 A ZA 2023/09330A ZA 202309330 A ZA202309330 A ZA 202309330A ZA 202309330 B ZA202309330 B ZA 202309330B
- Authority
- ZA
- South Africa
- Prior art keywords
- cells
- marker
- labelling
- status
- labelled
- Prior art date
Links
- 210000004369 blood Anatomy 0.000 title abstract 3
- 239000008280 blood Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000003550 marker Substances 0.000 abstract 9
- 238000002372 labelling Methods 0.000 abstract 7
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 6
- 210000004027 cell Anatomy 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000001580 bacterial effect Effects 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to a method for analysing a blood sample from a human for a disease, especially a bacteria-based disease, comprising: stimulating provided cells from the blood sample with bacterial antigens to induce at least one presence marker on T cells of the provided cells, labelling at least one of the induced presence markers on T cells in the provided cells, which presence marker is specifically formed on T cells which recognised bacterial antigen during the stimulation, labelling a first status marker and a further status marker on T cells in the provided cells that are specific for the activation status thereof, said status markers differing from one another and from the presence marker, evaluating a first labelling result of the labelling steps by analysis of the frequency of T cells having a labelled first status marker and a labelled presence marker based on a reference value and making a comparison with a first combination limit, evaluating at least one further labelling result of the labelling steps by analysis of the frequency of T cells having a labelled further status marker and a labelled presence marker based on a reference value and making a comparison with a further combination limit, forming an overall result from the evaluated labelling results and comparing the overall result with an overall limit.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102021203480.2A DE102021203480A1 (en) | 2021-04-08 | 2021-04-08 | Method of analyzing a blood sample for a disease |
| PCT/EP2022/058377 WO2022214371A1 (en) | 2021-04-08 | 2022-03-30 | Method for analyzing a blood sample for a disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202309330B true ZA202309330B (en) | 2024-05-30 |
Family
ID=81386898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/09330A ZA202309330B (en) | 2021-04-08 | 2023-10-05 | Method for analyzing a blood sample for a disease |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4320437A1 (en) |
| DE (1) | DE102021203480A1 (en) |
| WO (1) | WO2022214371A1 (en) |
| ZA (1) | ZA202309330B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2016009574A0 (en) | 2014-05-05 | 2016-11-30 | Univ Emory | Methods of diagnosing and treating tuberculosis |
| EP3555630B1 (en) * | 2016-12-14 | 2023-05-31 | Becton, Dickinson and Company | Methods and compositions for obtaining a tuberculosis assessment in a subject |
| WO2019165217A1 (en) * | 2018-02-22 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd153 and/or cd30 in infection |
| DE102018131696B4 (en) | 2018-12-11 | 2020-09-17 | Labor Berlin - Charité Vivantes Services GmbH | Method for the analysis of a blood sample from a person for tuberculosis disease |
-
2021
- 2021-04-08 DE DE102021203480.2A patent/DE102021203480A1/en active Pending
-
2022
- 2022-03-30 EP EP22718983.4A patent/EP4320437A1/en active Pending
- 2022-03-30 WO PCT/EP2022/058377 patent/WO2022214371A1/en active Application Filing
-
2023
- 2023-10-05 ZA ZA2023/09330A patent/ZA202309330B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022214371A1 (en) | 2022-10-13 |
| DE102021203480A1 (en) | 2022-10-13 |
| EP4320437A1 (en) | 2024-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602007003833D1 (en) | IMPROVED VITAMIN D MEASUREMENT | |
| TW200801202A (en) | Alpha-enolase specific antibody and method of use | |
| DE60233949D1 (en) | DIAGNOSTIC MARKERS FOR STROKE AND HARNTRAUMA AND METHOD OF USE THEREOF | |
| DE60335022D1 (en) | Internalizing antibodies specific for the RAAG10 cell surface target | |
| WO2006107962A3 (en) | Methods and products for evaluating an immune response to a therapeutic protein | |
| EP4282405A3 (en) | Detection of cancer biomarkers using nanoparticles | |
| EP3293522A3 (en) | Lipidomic biomarkers for identification of high-risk coronary artery disease patients | |
| Kostoulas et al. | Bayesian estimation of sensitivity and specificity of serum ELISA and faecal culture for diagnosis of paratuberculosis in Greek dairy sheep and goats | |
| NZ749272A (en) | Phospholipid ether analogs for the identification and isolation of circulating tumor cells | |
| Basketter et al. | Assessing the potency of respiratory allergens: uncertainties and challenges | |
| WO2004059282A3 (en) | Method and means for early detection of pregnancy in animals by combination testing | |
| DE68925058D1 (en) | Procedure for early detection of lung cancer | |
| ATE474227T1 (en) | DETERMINATION OF FELINE AND CANINE PROBNP | |
| WO2022120187A3 (en) | Method of determining resistance to checkpoint inhibitor therapies | |
| EP1977234A4 (en) | MOLECULES FOR THE TREATMENT OF LUNG DISEASES WITH AN IMMUNE REACTION WITH CONNECTING TISSUE IN THE LUNG | |
| BR112023000892A2 (en) | Inhibitor of an S100 PROTEIN FOR USE IN THE PREVENTION OR TREATMENT OF A MYELOPROLIFERATIVE NEOPLASIA, AGENT AND METHOD FOR IDENTIFYING AN INDIVIDUAL SUFFERING FROM A MYELOPROLIFERATIVE NEOPLASIA, AND METHODS FOR IDENTIFYING AN INDIVIDUAL AT RISK OF DEVELOPING MYELOFIBROSIS AND WHO BENEFITS FROM TREATMENT WITH AN INHIBITOR | |
| ZA202309330B (en) | Method for analyzing a blood sample for a disease | |
| Pan et al. | Identification of lethal Aspergillus at early growth stages based on matrix-assisted laser desorption/ionization time-of-flight mass spectrometry | |
| Soares Filho et al. | Evaluation of post-mortem diagnostic tests' sensitivity and specificity for bovine tuberculosis using Bayesian latent class analysis | |
| EA201490576A1 (en) | MOLECULAR MARKER FOR EARLY DIAGNOSTICS OF PLESUS MESOTHELIOMAS IN PATIENTS AND METHODS FOR ANALYSIS OF ITS EXPRESSION | |
| ZA202103675B (en) | Method for analyzing a blood sample from a human for a tuberculosis disease by detection of tb antigen-stimulated cd154 expression in combination with cd38, ki-67 or hla-dr | |
| Sin et al. | Changes of stress hormone cortisol after visiting the Gotjawal Forest in Jejudo | |
| CO2024013796A2 (en) | Cancer monitoring method using fragmentation profiles | |
| Beck et al. | Comparison of trichinelloscopy with a digestion method for the detection of Trichinella larvae in muscle tissue from naturally infected pigs with low level infections | |
| WO2007060240A3 (en) | Method for demonstrating presence or absence of markers (eef1a1 or mark3 )associated with the presence and/or the chemosensitivity of tumors |